Bosher HELMY, Sami ABDEL-WAHAB, Mostafa EL-SHAMY, Sameh M. Abdel MONEM, Hosam M. DAWOD

Combined percutaneous ethanol injection and mitoxantrone versus radiofrequency ablation in the treatment of hepatocellular carcinoma

New therapeutic choices have been developed for hepatocellular carcinoma, including percutaneous ablation therapy, transarterial chemoembolization, radiation therapy and molecular target therapy. Ablation of liver tumors is currently the main alternative to liver resection. This work aimed at comparing percutaneous combined local injection of ethanol and mitoxantrone versus percutaneous radiofrequency ablation in the treatment of Hepatocellular Carcinoma. This study included 124 patients with hepatocellular carcinoma, they were randomly divided into two groups; group I (64 patients) treated with local injection of ethanol plus mitoxantrone. Group II (60 patients) treated with radiofrequency ablation. Clinical assessment, laboratory evaluation and CT studies were performed to all patients prior to treatment and at 1, 3, 6, and 12 months' post treatment. The percentage of ablation in both groups at 1, 3, 6 and 12 months were 81.3%, 81.3%,76.6 and 71.9% in group I respectively versus 88.3%, 88.3, 85%% and 81.7% in group II respectively with no statistical significant difference between the two groups. Percentage of ablation in small tumors is higher than large tumors in both groups. Side effects and complications are statistically higher in group II than group I. Combination of percutaneous local injection of ethanol and mitoxantrone is comparable to radiofrequency ablation with less frequent complications in the treatment of Hepatocellular Carcinoma when surgical resection or liver transplantation is not amenable or available

PDF

___

Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. Cancer J Clin. 2005;55(2):74-108.

Franca AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FG. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37(11):1689-705.

Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J. Gastroenterol. 2003;9(9):1885- 91.

Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD,Lee KS, Chon CY, Moon YM. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with Holmium-166-Chitosan complex (Milican®) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12(2):543-8.

Wright AS, Mahvi, DM, Haemmerich DG, Lee FT. Minimally invasive approaches in management of hepatic tumors. Surg. Technol. Int. 2003;11:144-53.

Zamboglou N, Wurm R, Pape H. Simultaneous radiotherapy and intratumoral instillation of mitoxantrone in locoregional recurrence of head and neck carcinoma. Reg Cancer Treat. 1991;4:79-84.

Fox ME, Smith PJ. Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmacol. 1995;35(5):403-10.

Bruix J, Sherman M. AASLD practice guidlines: Management of Hepatocellular Carcinoma. Hepatology. 2005;42(5):1208-36.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.

Shiina S, Tagawa K, Unuma T, Fugino H, Uta y, Niwa Y, Hata Y, Komatsu Y, Shiratori Y, Terano A,et al. Percutaneous ethanol injection therapy of HCC: analysis of 77 patients. AJR Am J Roentgenol. 1990;155(6):1221-6.

Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C. Small hepatocellular carcinoma in cirrhosis:randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228(1):235-40.

Peng ZW, Zhang YJ, Chen MS, Lin XJ, Liang HH, Shi M. Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results. Eur J Surg Oncol. 2010;36(11):1054-60.

Aramaki, M.; Kawano, K.; Ohno, T, Sasaki A, Tahara K, Kai S, Iwashita Y, Kitano S. Microwave coagulation therapy for unresectable hepatocellular carcinoma. Hepatogastroenterology. 2004;51(60):1784-87.

Donckier V, Van Laethem JL, Ickx B, Van Gansbeke D, Goldman S, Gelin M. Local ablative treatments for liver metastases: the current situation. Acta Chir Belg. 2003;103(5):452-57.

Farrés MT, de Baere T, Lagrange C, Ramirez L, Rougier P, Munck JN, Roche A. Percutaneous mitoxantrone ınjection for primary and seconrary liver tumors. Cardiovasc Intervent Radiol. 1998;21(5):399- 403.

Bihery ASM Percutaneous Local Injection of Ethanol and/or Mitoxantron in Treatment of Hepatocellular Carcinoma. Thesis Submitted In partial fulfillment of MD Degree in Tropical Medicine. 2011.

Gad-El-Mawla N, El Zawahri H, Mokhtar N, Mohamed N, Abdel Monaem D, Faisal S. Epidemiologic and clinicopathologic features of HCC in egyptian patients. ASCO Annual Meeting 2001; Abstract no: 3036.

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557- 76.

Abdel-Wahab MF, Sultan A, El-Ebidy G. Hepatocellular carcinoma in MansouraEgypt: experience of 385 patients at a single center. Hepatogastroenterology. 2000;47(33):663-8.

Kew M. Hepatic tumors and cysts. In: Feldman M, Friedman LS, Sleisenger MH, eds. Gastrointestinal and Liver Disease. WB Saunders, Philadelphia. 2002;1577-1602

Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232(3):381-91.

Blum HE. Treatment of hepatocellular carcinoma: best practice and research. J Clin Gastrenerol. 2005;19(1):129-45.

Di Stasi M, Buscarini L, Livarghi T, Giorgio A, Salmi A, De Sio I, Brunello F, Solmi L, Caturelli E, Magnolfi F, Caremani M, Filice C. Percutaneous ethanol injection in the treatment of HCC .Amulticenter survey of evaluation practices and complication rates. Scand J Gastroentrol. 1997;32(11):1168-73.

Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, Sacchetto P, Gandini G, Rizzetto M. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol. 2008;43:727-35.

Livarghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumours with percutaneous radiofrequency ablation: complication encountered in a multicenter study. Radiology. 2003;226(2):441-51.

Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, Kohara K, Shigenobu S, Ishibashi K, Arima T. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97(5):1253-62.

Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farella N, Mariniello A, Esposito V, Coppola C, Giorgio V. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011;31:2291-5.

Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, Matsuo N, Hosogi Y. Hepatocellular carcinoma detected by iodized oil: Use of anticancer agents. Radiology. 1985;154:19-24.

Giovannini, M. Percutaneous alcohol ablation for liver metastasis. Semin. Oncol. 2002;29(2):192-5.

Seror O, N'Kontchou G, Tin Tin Htar M, Durand-Zaleski I, Trinchet JC, Sellier N, Beaugrand M. Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost. Gastroenterol Clin Biol. 2006;30(11):1265-73.

Fox, M.E. and Smith, P.J. Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmacol. 1995;35(5):403-10.

Hoffmann W, Reichel H, Schiebe M, Intrapericardial instillation of mitoxantrone in malignant pericarditis: Histopathological appearance. Reg Cancer Treat. 1993;2:91-9.

Cha CH, Lee FT Jr, Gurney JM, Markhardt BK, Warner TF, Kelcz F, Mahvi DM. CT versus sonography for monitoring radiofrequency ablation in a porcine liver. Am J Roentgenol. 2000;175(3):705-114

Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002; 95(9):1931-7.

Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151- 6.

Bouza C, López-Cuadrado T, Alcázar R, SazParkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9:31.

Song TJ, Ip EW Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004;127(5 Suppl 1):S248-60.